RBM17

Across TCGA pan-cancer cohorts, RBM17 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RBM17’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where RBM17 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RBM17 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

COAD, LUAD, and LSCC are the cancer types where RBM17 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RBM17 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	+0.436	<.001	11	view →
LUAD	Male	III,IV	+0.352	<.001	9	view →
LSCC	Male	All	+0.474	<.001	8	view →
HNSC	All	IV	+0.315	<.001	8	view →
CCRCC	All	III,IV	+0.085	<.001	7	view →
PDAC	Male	All	−0.168	.006	4	view →
OV	All	All	+0.400	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RBM17–COAD

Open the COAD breakdown →